.jpeg)
2026-02-28 03:31:21
Isatuximab (Sarclisa) is a CD38-targeting monoclonal antibody approved for relapsed/refractory and newly diagnosed Multiple Myeloma. Its mechanism involves apoptosis induction, ADCC immune killing, and enzymatic inhibition. Clinical data confirms extended Progression-Free Survival (PFS) and improved MRD negativity with combination regimens. This guide covers IV infusion protocols, Infusion-Related Reaction (IRR) management, and patient quality of life insights for optimized treatment decisions.
2026-02-09 04:16:06
As an agonist of the thrombopoietin receptor, eltrombopag has significant therapeutic effects in chronic ITP (adults and children), hepatitis C-related thrombocytopenia, and severe aplastic anemia. It can increase platelet count, reduce bleeding risk, assist in antiviral therapy, and promote hematopoietic reconstruction. Clinical data has verified its multi scenario application value.
2025-10-19 11:44:20
